| Identification | Back Directory | [Name]
Benzeneacetic acid, 3-pentyl- | [CAS]
1002101-19-0 | [Synonyms]
Setogepram
Fezagepras
(3-Pentylphenyl)acetic acid
Benzeneacetic acid, 3-pentyl-
2-(3-Pentylphenyl)acetic acid | [Molecular Formula]
C13H18O2 | [MDL Number]
MFCD24480577 | [MOL File]
1002101-19-0.mol | [Molecular Weight]
206.28 |
| Hazard Information | Back Directory | [Uses]
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2]. | [in vivo]
Fezagepras (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice[1]. | Animal Model: | Type 2 diabetes eNOS-/-db/db mice[1] | | Dosage: | 100 mg/kg/day | | Administration: | Given via daily gavage from 8-20 weeks | | Result: | Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved. |
| [References]
[1] Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365. DOI:10.1172/jci.insight.120365
[2] Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. DOI:10.1124/jpet.118.250068 |
|
| Company Name: |
Struchem Co., Ltd.
|
| Tel: |
0512-0512-63009836 15365350169 |
| Website: |
http://www.struchem.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|